NCT00629447View on ClinicalTrials.gov

Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients

NACompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

October 31, 2009

Conditions

Primary Brain Tumor

Interventions

DRUG

Innohep

The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.

Trial Locations (1)

27710

Duke University Health Systems, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Duke University

OTHER

NCT00629447 - Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients | Biotech Hunter | Biotech Hunter